Hepatitis B Global Clinical Trials Review, H2, 2016

Date: August 24, 2016
Pages: 785
Price:
US$ 2,500.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H0D716CE752EN
Leaflet:

Download PDF Leaflet

Hepatitis B Global Clinical Trials Review, H2, 2016

SUMMARY

GlobalData's clinical trial report, “Hepatitis B Global Clinical Trials Review, H2, 2016' provides an overview of Hepatitis B clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatitis B. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

REASONS TO BUY
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Report Guidance
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Hepatitis B to Infectious Disease Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Hepatitis B to Infectious Disease Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Hepatitis B Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Hepatitis B
Aug 02, 2016: ContraVir Reports Positive Data from Phase 1b Study of CMX157
Jul 21, 2016: Transgene to Continue Phase 1/1b Study with TG1050 in Chronic Hepatitis B Patients on the Recommendation of the Trial’s Safety Review Committee
Jun 22, 2016: Spring Bank Pharmaceuticals Doses the First Patient in the ACHIEVE Global Phase 2 Program of SB 9200 in Hepatitis B
Jun 21, 2016: ContraVir Doses First Patients in Head-to-Head Study of CMX157 vs. Viread for Treating Hepatitis B
Jun 07, 2016: Replicor announces publication of its REP 101 study demonstrating the therapeutic effect of NAPs and the achievement of functional control off treatment in human patients with chronic hepatitis B infection
Jun 07, 2016: Replicor announces publication of its REP 102 study demonstrating the therapeutic effect of NAPs and the achievement of functional control off treatment in human patients with chronic hepatitis B infection
Jun 01, 2016: ContraVir Initiates Head-to-Head Phase 2a Clinical Study of CMX157 vs. Viread for Treating Hepatitis B
Jun 01, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Publication of Myrcludex B Clinical Results in Journal of Hepatology
May 25, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Start Of Second Phase 2 Clinical Trial Of Myrcludex B In Chronic Hepatitis B/D Infection
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About GlobalData
Contact Us
Disclaimer
Source

LIST OF TABLES

Hepatitis B Therapeutics, Global, Clinical Trials by Region, 2016
Hepatitis B Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016
Hepatitis B Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016
Hepatitis B Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016
Hepatitis B Therapeutics Clinical Trials, Europe, Top Five Countries, 2016
Hepatitis B Therapeutics Clinical Trials, North America, Top Countries, 2016
Hepatitis B Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016
Hepatitis B Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016
Proportion of Hepatitis B to Infectious Disease Clinical Trials, G7 Countries (%), 2016
Hepatitis B Therapeutics, G7 Countries, Clinical Trials by Phase, 2016
Hepatitis B Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016
Proportion of Hepatitis B to Infectious Disease Clinical Trials, E7 Countries (%), 2016
Hepatitis B Therapeutics, E7 Countries, Clinical Trials by Phase, 2016
Hepatitis B Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016
Hepatitis B Therapeutics, Global, Clinical Trials by Phase, 2016
Hepatitis B Therapeutics, Global, Clinical Trials In Progress by Phase 2016
Hepatitis B Therapeutics, Global, Clinical Trials by Trial Status, 2016
Hepatitis B Therapeutics Clinical Trials, Global, by End Point Status, 2016
Hepatitis B Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
Hepatitis B Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016
Hepatitis B Therapeutics Clinical Trials, Global, Key Sponsors, 2016
Hepatitis B Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016
Hepatitis B Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016

LIST OF FIGURES

Hepatitis B Therapeutics, Global, Clinical Trials by Region (%), 2016
Hepatitis B Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016
Hepatitis B Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016
Hepatitis B Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016
Hepatitis B Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016
Hepatitis B Therapeutics Clinical Trials, North America, Top Countries (%), 2016
Hepatitis B Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016
Hepatitis B Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016
Proportion of Hepatitis B to Infectious Disease Clinical Trials, G7 Countries (%), 2016
Hepatitis B Therapeutics, G7 Countries, Clinical Trials by Phase, 2016
Hepatitis B Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016
Proportion of Hepatitis B to Infectious Disease Clinical Trials, E7 Countries (%), 2016
Hepatitis B Therapeutics, E7 Countries, Clinical Trials by Phase, 2016
Hepatitis B Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016
Hepatitis B Therapeutics, Global, Clinical Trials by Phase (%), 2016
Hepatitis B Therapeutics, Global, Clinical Trials In Progress by Phase, 2016
Hepatitis B Therapeutics, Global, Clinical Trials by Trial Status, 2016
Hepatitis B Therapeutics Clinical Trials, Global, by End Point Status, 2016
Hepatitis B Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
Hepatitis B Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016
Hepatitis B Therapeutics Clinical Trials, Global, Key Sponsors, 2016
Hepatitis B Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016
Hepatitis B Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016
GlobalData Methodology

COMPANIES MENTIONED

GlaxoSmithKline Plc
Gilead Sciences, Inc.
F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
Sanofi
Novartis AG
Merck & Co., Inc.
Bukwang Pharm.Co., Ltd.
Assembly Biosciences, Inc.
Dynavax Technologies Corporation
Skip to top


Hepatitis A Global Clinical Trials Review, H1, 2016 US$ 2,125.00 Mar, 2016 · 75 pages

Ask Your Question

Hepatitis B Global Clinical Trials Review, H2, 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: